These results indicate that lower doses of combined GTPs and SFN selectively inhibit ERα-negative breast cancer cells; however, the optimal doses required for the transcriptional activation of ERα remained to be determined in our subsequent studies. This evidence concerns the gene ESR1 and breast carcinoma.